Inmune Bio Inc. announced that the first patient has been treated in their phase I/II trial for metastatic castration-resistant prostate cancer at the West Los Angeles Veterans Administration Hospital.
AI Assistant
INMUNE BIO INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.